HK1144772A1 - Protopanaxadiol-type ginsenoside compositions and uses thereof - Google Patents

Protopanaxadiol-type ginsenoside compositions and uses thereof

Info

Publication number
HK1144772A1
HK1144772A1 HK10111249.4A HK10111249A HK1144772A1 HK 1144772 A1 HK1144772 A1 HK 1144772A1 HK 10111249 A HK10111249 A HK 10111249A HK 1144772 A1 HK1144772 A1 HK 1144772A1
Authority
HK
Hong Kong
Prior art keywords
protopanaxadiol
type ginsenoside
ginsenoside compositions
compositions
type
Prior art date
Application number
HK10111249.4A
Other languages
English (en)
Inventor
Thomas E Daley
Michael Tempesta
Original Assignee
Raptor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raptor Therapeutics Inc filed Critical Raptor Therapeutics Inc
Publication of HK1144772A1 publication Critical patent/HK1144772A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HK10111249.4A 2008-01-24 2010-12-02 Protopanaxadiol-type ginsenoside compositions and uses thereof HK1144772A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2331008P 2008-01-24 2008-01-24
PCT/US2009/000431 WO2009094177A1 (fr) 2008-01-24 2009-01-23 Compositions de ginsénoside de type protopanaxadiol et leurs utilisations

Publications (1)

Publication Number Publication Date
HK1144772A1 true HK1144772A1 (en) 2011-03-11

Family

ID=40578016

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10111249.4A HK1144772A1 (en) 2008-01-24 2010-12-02 Protopanaxadiol-type ginsenoside compositions and uses thereof

Country Status (14)

Country Link
US (1) US8440632B2 (fr)
EP (1) EP2254569B1 (fr)
JP (1) JP5523348B2 (fr)
KR (2) KR101648987B1 (fr)
CN (1) CN101977600B (fr)
AU (1) AU2009206753B2 (fr)
CA (1) CA2713104C (fr)
DK (1) DK2254569T3 (fr)
ES (1) ES2400491T3 (fr)
HK (1) HK1144772A1 (fr)
MY (1) MY160074A (fr)
NZ (1) NZ587134A (fr)
TW (1) TWI440463B (fr)
WO (1) WO2009094177A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5563285B2 (ja) * 2009-12-14 2014-07-30 ライオン株式会社 飲食品、医薬品、又は医薬部外品、並びに、プロトパナキサトリオールの安定化方法、及びプロトパナキサジオールの安定化方法
WO2013078371A2 (fr) 2011-11-22 2013-05-30 The Johns Hopkins University Procédés et compositions pour réduire la toxicité de l'alcool
KR101446743B1 (ko) * 2012-06-11 2014-10-01 한국생명공학연구원 실리마린을 유효성분으로 포함하는 알콜성 위궤양 예방 및 치료용 조성물
CN102727508B (zh) * 2012-07-15 2014-09-24 浙江大学 人参二醇皂苷组分制备及在防治帕金森氏病中的药物用途
US11338120B2 (en) 2012-08-29 2022-05-24 Palo Alto Investors LP Methods and devices for treating parasympathetic bias mediated conditions
WO2014178803A1 (fr) * 2013-04-29 2014-11-06 Alkoçlar Erdal Can Composition destinée au traitement de la toxicomanie alcoolique
KR101621356B1 (ko) * 2014-09-05 2016-05-17 한국과학기술원 진세노사이드 f2의 간 질환 예방 또는 치료 용도
DK3174378T3 (da) 2014-10-28 2018-01-29 Robust Seed Tech A&F Aktiebolag Forbedret fremgangsmåde til foraktivering af frø
PL3273952T3 (pl) 2015-03-26 2022-11-14 SEN-JAM Pharmaceutical LLC Kombinacja naproksenu i feksofenadyny w celu zahamowania objawów związanych z zatruciem alkoholem
KR101641477B1 (ko) * 2016-01-19 2016-07-20 이국진 홍삼 추출물을 이용한 커피나무의 재배방법
CN106511360A (zh) * 2016-12-02 2017-03-22 上海芮范生物科技有限公司 一种含有人参皂苷Rg3和水飞蓟素的组合物及药物
CN106619669B (zh) * 2016-12-02 2019-03-29 延边大学 原人参二醇皂苷在制备防治炎症疾病的药物中的应用
CN107441104B (zh) * 2017-08-24 2023-07-21 浙江大学 人参二醇皂苷Rb组分防治糖尿病并发症及代谢紊乱相关疾病的医药用途
KR102053208B1 (ko) * 2018-03-15 2019-12-06 숙명여자대학교 산학협력단 진세노사이드 Rb1 및 Rb2를 유효성분으로 함유하는 근육 재생용 조성물
US11000537B2 (en) * 2018-10-17 2021-05-11 Amorepacific Corporation Composition comprising novel ginsenoside
KR102672902B1 (ko) * 2018-10-31 2024-06-10 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 숙취 해소용 조성물
US11000538B2 (en) * 2018-10-31 2021-05-11 Amorepacific Corporation Composition for enhancing exercise ability or anti-fatigue comprising novel ginsenoside
CN109758464B (zh) * 2019-03-21 2019-10-25 淮阴师范学院 越南人参皂苷r4在制备神经退行性疾病治疗药物中的应用
EP4041269A1 (fr) 2019-10-10 2022-08-17 Zobrius Pharma AS Composition anti-gueule de bois améliorée, sa préparation et ses utilisations
KR102654669B1 (ko) * 2021-06-30 2024-04-04 경희대학교 산학협력단 실리디아닌을 포함하는 인삼 금 나노에멀젼 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1574806A (en) 1976-06-03 1980-09-10 Inverni Della Beffa Spa Production of purified ginseng extracts and pharmaceutical compositions containing the extracts
US4966893A (en) 1989-01-13 1990-10-30 Pang Peter K T Method for treatment of senile dementia
JPH04316448A (ja) 1991-04-12 1992-11-06 Iwatani Internatl Corp 人参微粉末の製造方法
US5547671A (en) * 1995-09-20 1996-08-20 Duthinh; Phu Anti-intoxication composition
JP3656972B2 (ja) * 1997-02-14 2005-06-08 丸善製薬株式会社 アルコール臭低減剤
US6083932A (en) 1997-04-18 2000-07-04 Cv Technologies Inc. Pharmaceutical compositions derived from ginseng and methods of treatment using same
US6156291A (en) 1997-08-28 2000-12-05 Cv Technologies Inc. Chemical and pharmacological standardization of herbal extracts
KR20020035855A (ko) 1999-08-30 2002-05-15 마쯔오 미쯔요시 약용인삼을 포함하는 뇌세포 또는 신경세포 보호제
CA2307393A1 (fr) * 2000-05-01 2001-11-01 The University Of British Columbia Chimiotherapie par administration d'un ginsenoside
CN1167424C (zh) 2000-11-18 2004-09-22 唐修文 三七人参皂甙肠溶片
US7011096B2 (en) * 2001-08-31 2006-03-14 Philip Morris Usa Inc. Oxidant/catalyst nanoparticles to reduce carbon monoxide in the mainstream smoke of a cigarette
US20030185910A1 (en) * 2002-02-08 2003-10-02 Taik Koo Yun Cancer preventive composition comprising ginsenoside glycosides of red ginseng
US6936283B2 (en) * 2003-07-25 2005-08-30 Langeland Bjoern T. Composition for stimulation of specific metallo-enzymes
WO2005012904A1 (fr) * 2003-08-01 2005-02-10 Aesgen, Inc. Compositions et methodes de suivi d'un traitement de cancer du sein
JP4777776B2 (ja) * 2003-08-18 2011-09-21 ユーユー インコーポレイテッド 酢を利用した人参製剤及びこれの製造方法
KR20050081247A (ko) 2004-02-12 2005-08-18 이처준 홍삼 및 흑삼을 이용한 해장국 제조 방법.
WO2005084392A2 (fr) 2004-03-03 2005-09-15 Convivia Formulations a base de 4-methylpyrazole destinees a inhiber l'intolerance a l'ethanol
KR100547253B1 (ko) 2004-05-29 2006-01-26 박명환 암 예방 및 치료에 유효한 진세노사이드 유도체
CN1698879B (zh) * 2005-06-21 2010-08-11 蔺益民 具有解酒护肝功能的产品及制备方法和用途
SI1909600T1 (sl) * 2005-07-29 2012-07-31 Tima Foundation Zmes za nadzor metabolizma alkohola in za zmanjšanje nevarnosti z alkoholom induciranih bolezni

Also Published As

Publication number Publication date
TW200936144A (en) 2009-09-01
AU2009206753B2 (en) 2014-07-03
AU2009206753A1 (en) 2009-07-30
WO2009094177A1 (fr) 2009-07-30
CA2713104A1 (fr) 2009-07-30
KR101648987B1 (ko) 2016-08-17
US8440632B2 (en) 2013-05-14
CN101977600A (zh) 2011-02-16
CA2713104C (fr) 2016-07-12
DK2254569T3 (da) 2013-02-25
EP2254569A1 (fr) 2010-12-01
KR20100111300A (ko) 2010-10-14
KR20160048228A (ko) 2016-05-03
CN101977600B (zh) 2013-02-27
EP2254569B1 (fr) 2012-11-28
ES2400491T3 (es) 2013-04-10
US20110065659A1 (en) 2011-03-17
TWI440463B (zh) 2014-06-11
MY160074A (en) 2017-02-15
NZ587134A (en) 2012-04-27
JP2011510075A (ja) 2011-03-31
JP5523348B2 (ja) 2014-06-18

Similar Documents

Publication Publication Date Title
HK1144772A1 (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
ZA201001300B (en) Antigen-asjuvant compositions and methods
IL210153A0 (en) Nutrigenomics methods and compositions
ZA201003696B (en) Compositions and devices
EP2219554A4 (fr) Dispositifs et compositions contenant de la progestérone
ZA201008887B (en) Oral compositions and uses thereof
IL212822A0 (en) Anti-cxcr1 compositions and methods
ZA201007920B (en) Oral compositions and uses thereof
GB0819530D0 (en) Methods and compositions
IL211204A0 (en) Mucoadherents compositions and their use
GB0721291D0 (en) Methods and compositions
TWI367763B (en) Compositions and devices
IL209027A0 (en) Vaccine compositions and uses thereof
GB0809912D0 (en) Novel compositions and uses thereof
GB0719526D0 (en) Compositions and methods
EP2247303A4 (fr) Compositions modulant l'hémostase et utilisations associées
GB0715428D0 (en) Compositions and uses thereof
GB0701170D0 (en) Compositions and uses thereof
GB0701171D0 (en) Compositions and uses thereof
GB0725264D0 (en) Compositions and uses thereof
GB2461611B (en) Composition and use thereof
GB0811250D0 (en) Methods and compositions
GB0909792D0 (en) Composition and uses thereof
GB0718825D0 (en) Salaris and tulearins and compositions and uses thereof
GB0810151D0 (en) Composition and their uses

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190123